We recently published 10 Stocks Jim Cramer Talked About. Abbott Laboratories (NYSE:ABT) is one of the stocks Jim Cramer ...

(Reuters) -Abbott will buy cancer test maker Exact Sciences in a deal valued at up to $23 billion, including debt, marking ...

Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences.

Shares of cancer diagnostic specialist Exact Sciences (NASDAQ: EXAS) rallied 50.7% this week through Thursday at 3:30 PM EDT.

The deal appears to be the biggest healthcare acquisition announced this the year, and would be Abbott’s largest since 2017.

Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share. Click here ...

Abbott's $23B Exact Sciences deal adds short-term risk and earnings dilution. Click here to read what this means for ABT ...

Abbott Laboratories agreed to acquire cancer-screening company Exact Sciences Corp., in a deal with a total equity value of ...

Abbott Laboratories $21 billion deal to acquire cancer test maker Exact Sciences could bolster the company’s diagnostic ...

Medical device maker Abbott Laboratories is nearing a potential takeover of cancer test maker Exact Sciences Corp , Bloomberg ...

In January, Exact Sciences CEO Kevin Conroy told us that 2025 was shaping up to be a transformative year for the diagnostics ...

Global healthcare leader Abbott announced Thursday that it has reached a $23 billion deal to acquire Exact Sciences.